Previous 10 | Next 10 |
ATLANTA, May 18, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether ImmunityBio, Inc. (“ImmunityBio,” or the “Company”) (NASDAQ: IBRX) complied with federal securities laws. On May 11, 2023, ImmunityBio disclosed that it received a comple...
SAN FRANCISCO, May 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/IBRX Contact An Attorney Now: IBRX@hbsslaw.com 844-9...
2023-05-17 11:23:13 ET Summary Being an extremely volatile stock, ImmunityBio, Inc. is not for all investors. Nevertheless, there are tremendous opportunities in ImmunityBio stock for investors who can stomach higher risks and substantial volatility. Based on the recent Comple...
SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2023 / Hagens Berman urges ImmunityBio, Inc. (NASDAQ:IBRX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/IBRX Contact An Attorney Now: IBRX@hbsslaw.com 844-916-0895 ImmunityBi...
2023-05-12 05:20:49 ET Summary ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Despite manufacturing deficiencies, the lack of additional FDA requests for precli...
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Click Here to Join Investigation. ...
SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/IBRX Contact An Attorney Now: IBRX@hbsslaw.com 844-9...
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ImmunityBio, Inc. (NASDAQ: IBRX) for potential securities law violations. Investors who have lost money in their ImmunityBio, Inc. investment should contact the firm to learn more about how they might recover those ...
2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...
2023-05-11 07:44:31 ET ImmunityBio ( NASDAQ: IBRX ) lost ~57% in the pre-market trading Thursday after disclosing that the FDA rejected a marketing application for its product candidate Anktiva as a combination therapy for a type of bladder cancer. Issuing a so-called comp...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...